文献速递骨质疏松与代谢性骨病

外源性褪黑素可能通过抑制衰老预防1型糖尿病诱导的骨丢失

Exogenous melatonin prevents type 1 diabetes mellitus-induced bone loss, probably by inhibiting senescence.
PubMed 文献 · Osteoporos Int · 2021-09-14

该研究在1型糖尿病小鼠和高糖培养的MC3T3-E1前成骨细胞中探讨褪黑素对糖尿病骨丢失的作用及机制。结果显示褪黑素可抑制衰老并防止骨丢失,其作用依赖MT1/MT2受体及Sirt1通路。提示靶向衰老可能为糖尿病骨质疏松提供新思路。

要点

  • 褪黑素可防止1型糖尿病小鼠的骨丢失并抑制前成骨细胞衰老。
  • 褪黑素的抗衰老作用依赖MT1/MT2受体及Sirt1表达上调。
  • 敲低Sirt1可阻断褪黑素的抗衰老效应。

核心结论

  • 外源性褪黑素可预防1型糖尿病诱导的骨丢失,其机制可能为抑制衰老。

研究设计与样本

  • C57BL/6小鼠单次腹腔注射160 mg/kg链脲佐菌素后,口服褪黑素或溶媒2个月并取材检测。
  • MC3T3-E1细胞在高糖条件下培养7天,再用褪黑素处理24小时。
  • 通过转染Sirt1特异性siRNA及MT1或MT2特异性shRNA质粒进行机制研究。

主要发现

  • 小鼠股骨总蛋白显示褪黑素可防止1型糖尿病小鼠的衰老。
  • micro-CT结果显示褪黑素可防止1型糖尿病小鼠的骨丢失。
  • 细胞实验显示褪黑素可防止高糖诱导的衰老,而敲低MT1或MT2可消除该效应。
  • 褪黑素上调Sirt1表达,敲低MT1或MT2后Sirt1显著降低;敲低Sirt1可阻断褪黑素的抗衰老效应。
  • 褪黑素促进CDK2、CDK4和CyclinD1表达并增加PRC表达,敲低MT1或MT2可消除这些效应。

临床怎么用

  • 对于1型糖尿病相关骨丢失,褪黑素可能通过抑制衰老发挥保护作用,但需进一步临床验证。
  • 靶向衰老(如Sirt1通路)可能是糖尿病骨质疏松研究的潜在方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Exogenous melatonin inhibited the senescence of preosteoblast cells in type 1 diabetic (T1D) mice and those cultured in high glucose (HG) by multiple regulations. Exogenous melatonin had a protective effect on diabetic osteoporosis, which may depend on the inhibition of senescence. INTRODUCTION: Senescence is thought to play an important role in the pathophysiological mechanisms underlying diabetic bone loss. Increasing evidence has shown that melatonin exerts anti-senescence effects. In this study, we investigated whether melatonin can inhibit senescence and prevent diabetic bone loss. METHODS: C57BL/6 mice received a single intraperitoneal injection of 160 mg/kg streptozotocin, followed by the oral administration of melatonin or vehicle for 2 months. Then, tissues were harvested and subsequently examined. MC3T3-E1 cells were cultured under HG conditions for 7 days and then treated with melatonin or not for 24 h. Sirt1-specific siRNAs and MT1- or MT2-specific shRNA plasmids were transfected into MC3T3-E1 cells for mechanistic study. RESULTS: The total protein extracted from mouse femurs revealed that melatonin prevented senescence in T1D mice. The micro-CT results indicated that melatonin prevented bone loss in T1D mice. Cellular experiments indicated that melatonin administration prevented HG-induced senescence, whereas knockdown of the melatonin receptors MT1 or MT2 abolished these effects. Sirt1 expression was upregulated by melatonin administration but significantly reduced after MT1 or MT2 was knocked down. Knockdown of Sirt1 blocked the anti-senescence effects of melatonin. Additionally, melatonin promoted the expression of CDK2, CDK4, and CyclinD1, while knockdown of MT1 or MT2 abolished these effects. Furthermore, melatonin increased the expression of the polycomb repressive complex (PRC), but knockdown of MT1 or MT2 abolished these effects. Furthermore, melatonin increased the protein levels of Sirt1, PRC1/2 complex-, and cell cycle-related proteins. CONCLUSION: This work shows that melatonin protects against T1D-induced bone loss, probably by inhibiting senescence. Targeting senescence in the investigation of diabetic osteoporosis may lead to novel discoveries.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gong Z, Da W, Tian Y, et al. Exogenous melatonin prevents type 1 diabetes mellitus-induced bone loss, probably by inhibiting senescence. Osteoporos Int. 2021. PMID: 34519833. doi:10.1007/s00198-021-06061-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。